Medicover Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Medicover wird ein jährliches Gewinn- und Umsatzwachstum von 37.8% bzw. 14.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 39.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.6% betragen.

Wichtige Informationen

37.8%

Wachstumsrate der Gewinne

39.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	32.3%
Wachstumsrate der Einnahmen	14.4%
Zukünftige Eigenkapitalrendite	18.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Apr 22

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Mar 05

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Feb 11

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Jun 12

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

May 27

Is Medicover (STO:MCOV B) Using Too Much Debt?

May 12

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Feb 16

Is Medicover (STO:MCOV B) Using Too Much Debt?

Jan 30

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Dec 30

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Dec 17

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Oct 30

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Oct 16

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Sep 09

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Jul 25

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Jul 12

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Jun 13

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

May 29

With EPS Growth And More, Medicover (STO:MCOV B) Is Interesting

Apr 20

Medicover (STO:MCOV B) Could Easily Take On More Debt

Apr 08

Medicover (STO:MCOV B) Is Doing The Right Things To Multiply Its Share Price

Mar 15

Is Now The Time To Look At Buying Medicover AB (publ) (STO:MCOV B)?

Feb 25

Gewinn- und Umsatzwachstumsprognosen

OM:MCOV B - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,725	97	145	309	2
12/31/2025	2,364	64	122	260	3
12/31/2024	2,039	28	92	216	3
3/31/2024	1,826	22	113	222	N/A
12/31/2023	1,746	18	95	205	N/A
9/30/2023	1,682	8	90	205	N/A
6/30/2023	1,610	6	75	202	N/A
3/31/2023	1,548	1	43	186	N/A
12/31/2022	1,510	12	30	170	N/A
9/30/2022	1,489	37	45	182	N/A
6/30/2022	1,455	59	67	195	N/A
3/31/2022	1,442	88	95	205	N/A
12/31/2021	1,377	102	115	217	N/A
9/30/2021	1,299	93	105	202	N/A
6/30/2021	1,226	90	91	176	N/A
3/31/2021	1,076	52	104	176	N/A
12/31/2020	998	26	83	155	N/A
9/30/2020	930	14	75	141	N/A
6/30/2020	879	4	53	122	N/A
3/31/2020	884	16	31	100	N/A
12/31/2019	844	23	24	87	N/A
9/30/2019	796	19	28	79	N/A
6/30/2019	751	19	39	86	N/A
3/31/2019	709	20	40	85	N/A
12/31/2018	672	22	33	74	N/A
9/30/2018	643	28	34	75	N/A
6/30/2018	620	26	22	61	N/A
3/31/2018	600	23	20	55	N/A
12/31/2017	580	19	N/A	50	N/A
9/30/2017	560	10	N/A	40	N/A
6/30/2017	540	9	N/A	36	N/A
3/31/2017	522	6	N/A	31	N/A
12/31/2016	497	4	N/A	26	N/A
12/31/2015	416	8	N/A	29	N/A
12/31/2014	365	4	N/A	22	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MCOV BDas prognostizierte Gewinnwachstum (37.8% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: MCOV BDie Erträge des Unternehmens (37.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.1% pro Jahr).

Hohe Wachstumserträge: MCOV BEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: MCOV BDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (2.1% pro Jahr).

Hohe Wachstumseinnahmen: MCOV BDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MCOV BDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.6%).

Medicover Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Consensus EPS estimates increase by 27%

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Consensus EPS estimates fall by 10%

Recent updates

General Legal Counsel recently sold kr1.2m worth of stock

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

New minor risk - Earnings quality

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Dividend of €0.12 announced

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Full year 2023 earnings: EPS exceeds analyst expectations

Now 24% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Consensus EPS estimates increase by 27%

Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Independent Chairman recently bought kr3.9m worth of stock

New minor risk - Earnings quality

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Chief Information Officer recently bought kr321k worth of stock

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

Is Medicover (STO:MCOV B) Using Too Much Debt?

Consensus EPS estimates fall by 10%

Now 21% undervalued after recent price drop

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 72%

Now 23% undervalued

Full year 2022 earnings: Revenues in line with analyst expectations

Medicover AB (publ) Proposes Dividend for 2022

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Consensus EPS estimates fall by 26%

Is Medicover (STO:MCOV B) Using Too Much Debt?

Investor sentiment improved over the past week

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Second quarter 2022 earnings: Revenues exceed analyst expectations

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Independent Chairman recently bought kr2.8m worth of stock

Medicover AB (publ) (OM:MCOV B) acquired Konzilijum.

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Medicover AB (publ) (OM:MCOV B) signed an agreement to acquire Übag Mvz Meindentist Gbr.

High number of new directors